Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-4050 DDI Study with Midazolam in Healthy Adults
NCT03637049Phase 1Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fezagepras in idiopathic pulmonary fibrosis (IPF) and Alström syndrome (ALMS), sponsored by Liminal BioSciences Inc. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration at Day 5, Area under the concentration-time curve from time zero to infinity at Day 5 and 2 more. Started Jul 2018; status: completed.
02
Drugs
fezagepras
03
Conditions
idiopathic pulmonary fibrosis (IPF)Alström syndrome (ALMS)
Beyond the preview
Go deeper on NCT03637049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03637049.